Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 11
2008 11
2009 17
2010 29
2011 38
2012 64
2013 62
2014 59
2015 72
2016 59
2017 64
2018 40
2019 41
2020 26
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

514 results
Results by year
Filters applied: . Clear all
Page 1
Anti-inflammatory Effect of AZD6244 on Acrolein-Induced Neuroinflammation.
Ho WC, Hsu CC, Huang HJ, Wang HT, Lin AM. Ho WC, et al. Mol Neurobiol. 2020 Jan;57(1):88-95. doi: 10.1007/s12035-019-01758-8. Epub 2019 Nov 30. Mol Neurobiol. 2020. PMID: 31786775
Consistently, AZD6244 reduced acrolein-induced elevations in COX-II mRNA and COX-II protein expression. ...Using a transwell migration assay, AZD6244 attenuated acrolein (5 muM)-induced migration of BV-2 cells and primary cultured microglia. ...
Consistently, AZD6244 reduced acrolein-induced elevations in COX-II mRNA and COX-II protein expression. ...Using a transwell migratio …
The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K. Song H, et al. Med Sci Monit. 2018 May 8;24:3002-3010. doi: 10.12659/MSM.910084. Med Sci Monit. 2018. PMID: 29737325 Free PMC article.
The present study evaluated the effect of vemurafenib in combination with the selective MEK1/2 inhibitor AZD6244 on cell survival and explored the mechanism underlying the combined effect of vemurafenib and AZD6244 on thyroid cancer cells harboring BRAFV600E. ...Co- …
The present study evaluated the effect of vemurafenib in combination with the selective MEK1/2 inhibitor AZD6244 on cell survival and …
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. Banerjee A, et al. Neuro Oncol. 2017 Aug 1;19(8):1135-1144. doi: 10.1093/neuonc/now282. Neuro Oncol. 2017. PMID: 28339824 Free PMC article. Clinical Trial.
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Gross AM, et al. N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187457 Free PMC article. Clinical Trial.
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Dombi E, et al. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. N Engl J Med. 2016. PMID: 28029918 Free PMC article. Clinical Trial.
BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (A
BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are …
Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation.
Zhang Q, Xiao H, Jin F, Li M, Luo J, Wang G. Zhang Q, et al. Oncol Lett. 2018 Jul;16(1):326-334. doi: 10.3892/ol.2018.8674. Epub 2018 May 9. Oncol Lett. 2018. PMID: 29928418 Free PMC article.
The combination of AZD6244 and cetuximab significantly reduced HT29 cell viability and proliferation compared with AZD6244 alone. ...Combination of AZD6244 with cetuximab significantly induced tumor cells apoptosis (14.61% vs. 8.99%, P=0.046). ...
The combination of AZD6244 and cetuximab significantly reduced HT29 cell viability and proliferation compared with AZD6244 alo …
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
de Oliveira LC, Ribeiro AM, Albarnaz JD, Torres AA, Guimarães LFZ, Pinto AK, Parker S, Doronin K, Brien JD, Buller MR, Bonjardim CA. de Oliveira LC, et al. Arch Virol. 2020 Mar;165(3):671-681. doi: 10.1007/s00705-020-04524-7. Epub 2020 Jan 16. Arch Virol. 2020. PMID: 31942645
The effectiveness of AZD6244 was observed even when the treatment of infected animals was initiated 1-2 days postinfection. ...These data demonstrate the potential of AZD6244 as a new therapeutic agent to treat DENV infection and possibly other flavivirus diseases.. …
The effectiveness of AZD6244 was observed even when the treatment of infected animals was initiated 1-2 days postinfection. ...These …
Selumetinib: First Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2020 Jun;80(9):931-937. doi: 10.1007/s40265-020-01331-x. Drugs. 2020. PMID: 32504375 Review.
Selumetinib (KOSELUGO(TM); AZD6244, ARRY-142886) is a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor being developed by AstraZeneca for the treatment of tumours associated with neurofibromatosis and various cancers. ...
Selumetinib (KOSELUGO(TM); AZD6244, ARRY-142886) is a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor being developed by …
514 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page